Some stem cells can lay dormant for more than two weeks in a dead person and then be revived to divide into new, functioning cells, scientists in France said.
The research, published in the journal Nature Communications, unlocks further knowledge about the versatility of these cells, touted as a future source to replenish damaged tissue.
“Remarkably, skeletal muscle stem cells can survive for 17 days in humans and 16 days in mice, post mortem well beyond the 1-2 days currently thought,” they said in a statement.
The stem cells retained their ability to differentiate into perfectly functioning muscle cells, they found.
Bioengineered organs may redefine transplants for humans someday, and even allow damaged organs to regenerate.
Northwestern University researchers are in the beginning stages of bioengineering tissues and entire organs from stem cells of adult rats and mice, said Dr. Jenny Zhang. Zhang directs the Microsurgical Core within the Comprehensive Transplant Center at Feinberg.
Once engineered, Zhang said her team will be able to test the functionality of such organs as transplants in the rodents. For now, Zhang and fellow researchers are using a biodegradable scaffold, a kind-of-skeleton of an organ with all living cells removed, to test the model.
By developing a
Scientists in the US have made a major breakthrough that has the potential for people with brain damage, caused by epilepsy or Parkinson’s for example, to use their own brain stem cells as a treatment.
Steven Roper of the University of Florida discovered that stem cells from the human brain that were transplanted into the brains of newborn rats matured and were able to function just like native rat cells.
The researchers found that the adult stem cells had the ability to turn into all types of brain tissue in the rats, including the neocortex, which deals with higher processing, and
Doctors may soon be able to ‘draw’ new bone, skin and muscle on to patients, after scientists created a pen-like device that can apply human cells directly on to seriously injured people.
The device contains stem cells and growth factors and will give surgeons greater control over where the materials are deposited.
It will also reduce the time the patient is in surgery by delivering live cells and growth factors directly to the site of injury, accelerating the regeneration of functional bone and cartilage, scientists said.
CHA Bundang Medical Center has become the first in Asia (the second in the world) to confirm that the transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells is effective in treating age-related macular degeneration (AMD) and Stargardt disease (juvenile macular degeneration) without causing dangerous side effects. Hence CHA Bundang Medical Center is now on the fast track to developing the world’s first hESC-based therapeutic product.
A Korean research team, led by Professor Song Won-Kyung from CHA Bundang Medical Center, and CHA Biotech (a leading S. Korea-based biotechnology firm focused on stem cell therapies) jointly issued an